XLO
Xilio Therapeutics, Inc.Marquee-fund ownership over time
This quarter's activity
Current holders
Sorted by tenure (longest first)| Fund | First disclosed | Held | Entry price | Latest close | Return on entry |
|---|---|---|---|---|---|
| Renaissance Technologies re-entered | Q3 2024(8Q snapshot) | 7Q | $0.00 | $8.15 | — |
“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.
Past holders
Funds that exited at some point| Fund | Last entry | Exited | Entry → Exit | Return |
|---|---|---|---|---|
| Citadel Advisors 2× in & out | Q1 2026 | Q2 2026 | — | +0% |
| Two Sigma Investments | Q4 2024 | Q2 2026 | — | +0% |
| Point72 Asset Management | Q1 2026 | Q2 2026 | — | +0% |
| Millennium Management 2× in & out | Q2 2025 | Q3 2025 | — | +0% |
Insider activity
Form 4 — officers, directors, 10%+ ownersFiled within two business days of each transaction by anyone with material insider status at Xilio Therapeutics, Inc.. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.
30d / 90d windows measured from Apr 16, 2026 — the most recent Form 4 on file — not from today.
- Form 40001193125-26-159316Apr 16, 2026
- Form 40001193125-26-131745Mar 30, 2026
- Form 40001123292-26-000187Feb 17, 2026
- Form 40001193125-26-002520Jan 5, 2026
- Form 40001193125-26-002518Jan 5, 2026
- Form 40001193125-26-002517Jan 5, 2026
- Form 40001193125-26-002512Jan 5, 2026
- Form 40001123292-25-000675Dec 1, 2025
- Form 40001193125-25-297207Nov 25, 2025
- Form 40001193125-25-297204Nov 25, 2025
- Form 40001193125-25-297205Nov 25, 2025
- Form 40001193125-25-297203Nov 25, 2025
- Form 40001415889-25-017705Jun 18, 2025
- Form 40001415889-25-017704Jun 18, 2025
- Form 4/Aamend0001415889-25-017703Jun 18, 2025
Fundamentals
XBRL · Xilio Therapeutics, Inc.Annual figures sourced directly from Xilio Therapeutics, Inc.'s 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.
Recent SEC filings
10-K · 10-Q · 8-K · 13D/G · proxyThe most recent material filings for Xilio Therapeutics, Inc. — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.
- S-3/ARegistration (shelf, amended)May 27, 2026
- S-3Registration (shelf)May 12, 2026
- 10-QQuarterly reportMay 12, 2026
- 8-KMaterial eventMay 12, 2026
- DEF 14AProxy statementApr 28, 2026
- 8-KMaterial eventApr 16, 2026
- 10-KAnnual reportMar 23, 2026
- 8-KMaterial eventMar 23, 2026
- 8-KMaterial eventMar 12, 2026
- 8-KMaterial eventMar 9, 2026
- 8-KMaterial eventFeb 24, 2026
- 8-KMaterial eventFeb 12, 2026
- DEF 14AProxy statementJan 26, 2026
- 8-KMaterial eventJan 8, 2026
- 8-KMaterial eventJan 5, 2026
Trade history
Every open→close lifecycle across tracked funds| Fund | Open date | Close date | Open price | Close price / current | Return |
|---|---|---|---|---|---|
| Renaissance Technologies | Q2 2026 | open | $8.81 | $8.15 | -7% |
| Citadel Advisors | Q1 2026 | Q2 2026 | $0.00 | — | +0% |
| Point72 Asset Management | Q1 2026 | Q2 2026 | $0.00 | — | +0% |
| Millennium Management | Q2 2025 | Q3 2025 | $0.00 | — | +0% |
| Citadel Advisors | Q1 2025 | Q2 2025 | $0.00 | — | +0% |
| Two Sigma Investments | Q4 2024 | Q2 2026 | $0.00 | — | +0% |
| Millennium Management | Q3 2024 | Q1 2025 | $0.00 | — | +0% |
| Renaissance Technologies | Q3 2024 | Q2 2026 | $0.00 | — | +0% |
- Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
- Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
- “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
- Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
- Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.